Yeast whole glucan particle (WGP) β-glucan in conjunction with antitumour monoclonal antibodies to treat cancer

Expert Opinion on Biological Therapy

Volumn 5, Issue 5, 2005, Pages 691-702

  Yan, Jun ^a   Allendorf, Daniel J ^b   Brandley, Brian ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b NONE

Author keywords

glucan; Antitumour mAbs; Biological response modifier; Chemotaxis; Complement receptor 3 (CR3); Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GLUCAN; BIOLOGICAL RESPONSE MODIFIER; CETUXIMAB; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT IC3B FRAGMENT; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; MOLECULAR MECHANICS; NEUTROPHIL; NONHUMAN; REVIEW; SURVIVAL TIME; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BETA-GLUCANS; HUMANS; NEOPLASMS; YEASTS;

ANIMALIA;

EID: 20344401814     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.5.691     Document Type: Review

References (72)

1. PARDOLL D, ALLISON J: Cancer immunotherapy: breaking the barriers to harvest the crop. Nat. Med. (2004) 10(9):887-892.
2. ROBBINS PF, EL-GAMIL M, LI YF et al.: Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J. Immunol. (2002) 169(10):6036-6047.
3. CORDON-CARDO C, FUKS Z, DROBNJAK M et al.: Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. (1991) 51(23 Pt 1):6372-6380.
4. GARRIDO F, CABRERA T, CONCHA A et al.: Natural history of HLA expression during tumour development. Immunol. Today (1993) 14(10):491-499.
5. LEYLAND-JONES B: Trastuzumab: hopes and realities. Lancet Oncol. (2002) 3(3):137-144.
6. RANSON M, SLIWKOWSKI MX: Perspectives on anti-HER monoclonal antibodies. Oncology (2002) 63(Suppl. 1):17-24.
7. PLOSKER GL, FIGGITT DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs (2003) 63(8):803-843.
8. ROSS JS, SCHENKEIN DP, PIETRUSKO R et al.: Targeted therapies for cancer 2004. Am. J. Clin. Pathol. (2004) 122(4):598-609.
9. GELDERMAN KA, TOMLINSON S, ROSS GD, GORTER A: Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. (2004) 25(3):158-164.
10. JOHNSON P, GLENNIE M: The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. (2003) 30(1 Suppl. 2):3-8.
11. MILENIC DE, BRECHBIEL MW: Targeting of radio-isotopes for cancer therapy. Cancer Biol. Ther. (2004) 3(4):361-370.
12. ZHANG H, RICHTER M, GREENE MI: Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Cancer Biol. Ther. (2003) 2(4Suppl. 1):S122-S126.
13. BASELGA J, GIANNI L, GEYER C et al.: Future options with trastuzumab for primary systemic and adjuvant therapy Semin. Oncol. (2004) 31(5Suppl. 10):51-57.
14. TANABE H, IMAI N, TAKECHI K: [Studies on usefulness of postoperative adjuvant chemotherapy with lentinan in patients with gastrointestinal cancer]. Nippon Gan Chiryo Gakkai Shi (1990) 25(8):1657-1667.
15. KIMURA Y, TOJIMA H, FUKASE S, TAKEDA K: Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta. Otolaryngol. Suppl. (1994) 511:192-195.
16. MATSUOKA H, SEO Y, WAKASUGI H, SAITO T, TOMODA H: Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. (1997) 17(4A):2751-2755.
17. DI LUZIO NR, WILLIAMS DL, MCNAMEE RB, EDWARDS BF, KITAHAMA A: Comparative tumor-inhibitory and anti-bactetial activity of soluble and particulate glucan. Int. J. Cancer (1979) 24(6):773-779.
18. HUNTER JT, MELTZER MS, RIBI E et al.: Glucan: attempts to demonstrate therapeutic activity against five syngeneic tumors in guinea pigs and mice. J. Natl Cancer Inst. (1978) 60(2):419-424.
19. ROSS GD, CAIN JA, MYONES BL, NEWMAN SL, LACHMANN PJ: Specificity of membrane complement receptor type three (CR3) fot beta-glucans. Complement (1987) 4(2):61-74. Results suggest the role of CR3 in particulate β-glucan-mediated responses. Neutrophil ingestion of yeast-derived particulate glucan or neutrophil superoxide burst was blocked by anti-CR3 mAb. The superoxide burst response to β-glucan particles was completely absent with neutrophils from patients with an inherited deficiency of CR3.
20. THORNTON BP, VETVICKA V, PITMAN M, GOLDMAN RC, ROSS GD: Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. (1996) 156(3):1235-1246. Results show that CR3 (Mac-1, CD11b/CD18) served as the β-glucan receptor through lectin sites.
21. VETVICKA V, THORNTON BP, ROSS GD: Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. (1996) 98(1):50-61. Results suggest that soluble β-glucan induced a primed state of CR3 that could trigger the killing of iC3b-target cells that were otherwise resistant to cytotoxicity in vitro.
22. YAN J, VETVICKA V, XIA Y et al.: Beta-glucan, a 'specific' biologic response modifier that uses antibodies to target tumors fot cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol. (1999) 163(6):3045-3052. Results suggest that β-glucan-mediated tumour therapy requires both iC3b deposition on tumour cells mediated by natural antibodies and polysaccharide β-glucan. The requirement for C3 on tumours and CR3 on leukocytes was highlighted by therapy failures in C3- or CR3-deficient mice.
23. XIA Y, ROSS GD: Generation of tecombinanr fragments of CD11b expressing the functional beta-glucan-binding lectin site of CR3 (CD11WCD18). J. Immunol. (1999) 162(12):7285-7293. Recombinant CD11b was generated to further characterise the β-glucan binding site.
24. XIA Y, VETVICKA V, YAN J et al.: The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. (1999) 162(4):2281-2290.
25. WASSER SP, WEIS AL: Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit. Rev. Immunol. (1999) 19(1):65-96.
26. GAWRONSKI M, PARK JT, MAGEE AS, CONRAD H: Microfibrillar structure of PGG-glucan in aqueous solution as triple-helix aggregates by small angle X-ray scattering. Biopolymers (1999) 50(6):569-578.
27. WILLIAMS DL, PRETUS HA, MCNAMEE RB et al.: Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology (1991) 22(3):139-155. Characterisation of soluble yeast β-glucan.
28. ENSLEY HE, TOBIAS B, PRETUS HA et al.: NMR spectral analysis of a water-insoluble (1- > 3)-beta-D-glucan isolated from Saccharomyces cerevisiae. Carbohydr. Res. (1994) 258:307-311.
29. OSUMI M: The ultrastructure of yeast: cell wall structure and formation. Micron (1998) 29(2-3):207-233.
30. CASSONE A, BISTONI F, CENCI E et al.: Immunopotentiation of anticancer chemotherapy by Candida albicans, other yeasts and insoluble glucan in an experimental lymphoma model. Sabouraudia (1982) 20(2):115-125.
31. WILLIAMS DL, MCNAMEE RB, JONES EL et al.: A method for the solubilization of a (1-3)-beta-D-glucan isolated from Saccharomyces cerevisiae. Carbohydr. Res. (1991) 219:203-213.
32. BABINEAU TJ, MARCELLO P, SWAILS W et al.: Randomized Phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. (1994) 220(5):601-609.
33. BABINEAU TJ, HACKFORD A, KENLER A et al.: A Phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch. Surg. (1994) 129(11):1204-1210.
34. TZIANABOS AO, CISNEROS RL: Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. Ann. NY Acad. Sci. (1996) 797:285-287.
35. LIANG J, MELICAN D, CAFRO L et al.: Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int. J. Immunopharmacol. (1998) 20(11):595-614.
36. PATCHEN ML, VAUDRAIN T, CORREIRA H, MARTIN T, REESE D: In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Exp. Hematol. (1998) 26(13):1247-1254.
37. REICHNER JS, FITZPATRICK PA, WAKSHULL E, ALBINA JE: Receptor-mediated phagocytosis of rat macrophages is regulated differentially for opsonized particles and non-opsonized particles containing beta-glucan. Immunology (2001) 104(2):198-206.
38. MARKIEWICZ MA, KAST WM: Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest. (2004) 22(3):417-434.
39. NIEHANS GA, CHERWITZ DL, STALEY NA, KNAPP DJ, DALMASSO AP: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. (1996) 149(1):129-142.
40. VARSANO S, FROLKIS I, RASHKOVSKY L, OPHIR D, FISHELSON Z: Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation. Am. J. Respir. Cell Mol. Biol. (1996) 15(6):731-737.
41. LI L, SPENDLOVE I, MORGAN J, DURRANT LG: CD55 is over-expressed in the tumour environment. Br. J. Cancer (2001) 84(1):80-86.
42. ROSS GD: Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Crit. Rev. Immunol. (2000) 20(3):197-222.
43. KLEIN E, DI RENZO L, YEFENOF E: Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol. Immunol. (1990) 27(12):1343-1347.
44. ROSS GD, VETVICKA V: CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin. Exp. Immunol. (1993) 92(2):181-184.
45. HONG F, HANSEN RD, YAN J et al.: Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. (2003) 63(24):9023-9031. Five mouse syngeneic tumour models were used to test the efficacy of combined soluble yeast β-glucan in combination with antitumour mAbs.
46. HONG F, YAN J, BARAN JT et al.: Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. (2004) 173(2):797-806. Cellular and molecular mechanisms of action have been demonstrated for combined oral-administered β-glucan with antitumour mAbs.
47. YAN J, VETVICKA V, XIA Y et al.: Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan. Immunopharmacology (2000) 46(1):39-54. Results suggest that soluble β-glucan exhibited rapid clearance to the liver in normal mice, whereas clearance in CR3-KO mice was significantly reduced.
48. BROWN GD, HERRE J, WILLIAMS DL et al.: Dectin-1 mediates the biological effects of beta-glucans J. Exp. Med. (2003) 197(9):1119-1124. The experimental data demonstrate that TNF-α secretion by macrophages was dependent on Toll-like receptor 2 (TLR2), MyD88 and Dectin-1. This finding was novel in that TLR2 alone was not sufficient to mediate cytokine expression, and suggested that Dectin-1 may have a role in innate immunity as a pattern-recognition receptor of non-opsonised β-glucans.
49. TAYLOR PR, BROWN GD, REID DM et al.: The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J. Immunol. (2002) 169(7):3876-3882.
50. VETVICKA V, THORNTON BP, WIEMAN TJ, ROSS GD: Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18). J. Immunol. (1997) 159(2):599-605. In vitro experiments demonstrated that priming of NK cell CR3 with small soluble yeast β-glucan enabled the killing of iC3b-opsonised tumour cell lines and mammary carcinoma cells from freshly excised tumours.
51. ROBERTSON MJ, RITZ J: Biology and clinical relevance of human natural killer cells. Blood (1990) 76(12):2421-2438.
52. PAPAMICHAIL M, PEREZ SA, GRITZAPIS AD, BAXEVANIS CN: Natural killer lymphocytes: biology, development, and function. Cancer Immunol. Immunother. (2004) 53(3):176-186.
53. EHRENGRUBER MU, GEISER T, DERANLEAU DA: Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett. (1994) 346(2-3):181-184.
54. JAGELS MA, CHAMBERS JD, ARFORS KE, HUGLI TE: C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood (1995) 85(10):2900-2909.
55. PETERING H, KOHL J, WEYERGRAF A et al.: Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a. J. Immunol. (2000) 164(7):3783-3789.
56. ZWIRNER J, GOTZE O, BEGEMANN G et al.: Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology (1999) 97(1):166-172.
57. EMBER JA, HUGLI TE: Complement factors and their receptors. Immunopharmacology (1997) 38(1-2):3-15.
58. HARIBABU B, VERGHESE MW, STEEBER DA et al.: Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J. Exp. Med. (2000) 192(3):433-438.
59. NANBA H, KURODA H: Antitumor mechanisms of orally administered shiitake fruit bodies. Chem. Pharm. Bull. (Tokyo) (1987) 35(6):2459-2464.
60. SUZUKI I, SAKURAI T, HASHIMOTO K et al.: Inhibition of experimental pulmonary metastasis of Lewis lung carcinoma by orally administered beta-glucan in mice. Chem. Pharm. Bull. (Tokyo) (1991) 39(6):1606-1608.
61. CHEUNG NK, MODAK S: Oral (1- > 3),(1- > 4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res. (2002) 8(5):1217-1223. In vivo human neuroblastoma xenograft athymic nude mouse model demonstrated the therapeutic efficacy of combining barley β-glucan with anti-GD2 mAb 3F8.
62. CHEUNG NK, MODAK S, VICKERS A, KNUCKLES B: Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother. (2002) 51(10):557-564.
63. KO EC, WANG X, FERRONE S: Immunotherapy of malignant diseases. Challenges and strategies. Int. Arch. Allergy Immunol. (2003) 132(4):294-309.
64. ROSS GD, VETVICKA V, YAN J, XIA Y, VETVICKOVA J: Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology (1999) 42(1-3):61-74.
65. SIER CF, GELDERMAN KA, PRINS FA, GORTER A: Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int. J. Cancer (2004) 109(6):900-908. Results suggest that β-glucan enhanced the killing of renal cell carcinoma micrometastases when used in combination with mAb.
66. FOON KA, CHAKRABORTY M, JOHN WJ et al.: Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest. (1995) 96(1):334-342.
67. KARANIKAS V, HWANG LA, PEARSON J et al.: Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. (1997) 100(11):2783-2792.
68. NICHOLSON S, BOMPHRAY CC, THOMAS H et al.: A Phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol. Immunother. (2004) 53(9):809-816.
69. SPIRIDON CI, GHETIE MA, UHR J et al.: Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. (2002) 8(6):1720-1730.
70. DUTTA T, SPENCE A, LAMPSON LA: Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains. J. Neurooncol. (2003) 64(1-2):31-44.
71. KAUFMAN HL, DISIS ML: Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J. Clin. Invest. (2004) 113(5):664-667.
72. HARIBABU B, RICHARDSON RM, VERGHESE MW et al.: Function and regulation of chemoattractant receptors. Immunol. Res. (2000) 22(2-3):271-279.